Profile data is unavailable for this security.
About the company
CHINA RESOURCES PHARMACEUTICAL GROUP LIMITED is a Hongkong-based investment holding company. The Company, along with its subsidiaries, is principally engaged in the research and development, manufacturing, distribution and retail of pharmaceutical and other healthcare products. The Company mainly operates through three segments. Pharmaceutical Manufacturing segment is engaged in the research and development, manufacturing and sale of pharmaceutical and other healthcare products. Pharmaceutical Distribution segment is engaged in the provision of distribution solutions to pharmaceutical manufacturers and dispensers, such as hospitals and other medical institutions, distributors and retail pharmacies. Pharmaceutical Retail segment is involved in the operation of retail pharmacies in China and Hongkong.
- Revenue in HKD (TTM)269.40bn
- Net income in HKD4.06bn
- Incorporated2007
- Employees72.76k
- LocationChina Resources Pharmaceutical Group LtdRoom 4104-05, 41F,China Resources BuldngNo. 26, Harbour Road, Wan Chai Hong KongHKG
- Phone+852 25938991
- Fax+852 25938992
- Websitehttps://www.crpharm.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Simcere Pharmaceutical Group Ltd | 6.82bn | -1.19bn | 17.31bn | 6.41k | -- | 2.35 | -- | 2.54 | -0.4532 | -0.4532 | 2.65 | 2.92 | 0.5198 | 2.19 | 2.64 | 970,421.30 | -9.04 | 10.17 | -11.71 | 15.60 | 77.02 | 78.82 | -17.40 | 17.50 | 1.88 | 0.4721 | 0.1461 | 46.68 | 4.49 | 7.92 | -23.22 | -0.5213 | 23.93 | -- |
| The United Laboratories Intl. Hldgs Ltd. | 15.06bn | 3.13bn | 18.28bn | 15.00k | 5.85 | 1.26 | 4.89 | 1.21 | 1.72 | 1.72 | 8.29 | 8.00 | 0.6578 | 3.30 | 5.67 | 1,004,211.00 | 13.65 | 7.89 | 20.72 | 12.64 | 46.15 | 44.17 | 20.75 | 12.73 | 1.72 | -- | 0.1532 | 28.99 | 21.22 | 12.84 | 70.85 | 31.66 | 24.19 | 46.04 |
| China Medical System Holdings Ltd | 7.54bn | 1.49bn | 18.76bn | 5.78k | 12.57 | 1.09 | 10.82 | 2.49 | 0.6119 | 0.6119 | 3.08 | 7.08 | 0.384 | 2.89 | 5.65 | 1,322,918.00 | 7.51 | 18.44 | 8.53 | 21.14 | 74.13 | 75.47 | 19.56 | 34.26 | 3.97 | -- | 0.0667 | 40.14 | -12.43 | 8.08 | -26.33 | 5.35 | 38.69 | 5.19 |
| Zai Lab Ltd | 2.77bn | -2.11bn | 22.54bn | 2.18k | -- | 3.93 | -- | 8.14 | -2.16 | -2.16 | 2.84 | 5.28 | 0.3507 | 3.11 | 7.77 | -- | -26.70 | -37.72 | -33.48 | -42.72 | 63.37 | 64.75 | -76.13 | -282.44 | 2.87 | -- | 0.1447 | -- | 24.03 | 360.03 | 24.51 | -- | -3.45 | -- |
| HUTCHMED (China) Ltd | 4.75bn | -326.66m | 24.32bn | 1.97k | -- | 4.22 | -- | 5.12 | -0.3887 | -0.3887 | 5.51 | 6.61 | 0.4775 | 7.10 | 4.15 | 2,391,330.00 | -3.30 | -14.35 | -4.65 | -20.43 | 41.67 | 36.57 | -6.91 | -31.44 | 2.68 | -- | 0.0984 | -- | 96.52 | 31.38 | 127.93 | -- | 38.65 | -- |
| WuXi XDC Cayman Inc | 3.01bn | 639.28m | 31.67bn | 1.50k | 50.27 | 4.91 | 43.50 | 10.53 | 0.5252 | 0.5252 | 2.66 | 5.38 | 0.5586 | 21.31 | 2.85 | 2,551,697.00 | 11.88 | -- | 15.43 | -- | 30.96 | -- | 21.27 | -- | 4.02 | -- | 0.0113 | -- | 114.44 | -- | 82.07 | -- | -- | -- |
| China Resources Pharmaceutical Group Ltd | 269.40bn | 4.06bn | 34.11bn | 72.76k | 8.40 | 0.656 | 2.74 | 0.1266 | 0.6461 | 0.6461 | 42.88 | 8.28 | 0.966 | 6.09 | 3.28 | 3,691,123.00 | 3.19 | 3.02 | 12.13 | 11.35 | 15.78 | 15.72 | 3.31 | 2.87 | 1.12 | 11.50 | 0.4396 | 24.73 | 12.16 | 8.86 | 10.11 | 2.80 | 13.58 | 7.05 |
Data as of Nov 22 2024. Currency figures normalised to China Resources Pharmaceutical Group Ltd's reporting currency: Hong Kong Dollar HKD
5.31%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Norges Bank Investment Managementas of 30 Jun 2024 | 108.27m | 1.72% |
| The Vanguard Group, Inc.as of 06 Nov 2024 | 61.37m | 0.98% |
| Dimensional Fund Advisors LPas of 07 Nov 2024 | 40.10m | 0.64% |
| BlackRock Fund Advisorsas of 07 Nov 2024 | 28.30m | 0.45% |
| The Caisse de d�p�t et placement du Qu�becas of 31 Dec 2023 | 21.82m | 0.35% |
| BlackRock Advisors (UK) Ltd.as of 08 Nov 2024 | 18.05m | 0.29% |
| HSBC Global Asset Management (UK) Ltd.as of 07 Nov 2024 | 15.91m | 0.25% |
| Yinhua Fund Management Co., Ltd.as of 30 Jun 2024 | 15.14m | 0.24% |
| Bosera Asset Management Co., Ltd.as of 30 Jun 2024 | 12.35m | 0.20% |
| Geode Capital Management LLCas of 14 Nov 2024 | 12.18m | 0.19% |
More ▼
Data from 30 Jun 2024 - 11 Nov 2024Source: FactSet Research Systems Inc.
